KIDNEY DYSFUNCTION IN COPD WITH COMORBID ARTERIAL HYPERTENSION: BIOMARKERS, CLINICAL PATTERNS, AND TREATMENT OPTIMIZATION
- Authors
-
-
Khalimova Kh. Kh.
Department of Internal Medicine, Republic of Uzbekistan Tashkent State Medical University
Author
-
Gadayev A. G.
Department of Internal Medicine, Republic of Uzbekistan Tashkent State Medical University
Author
-
Gadayeva N. A.
Department of Internal Medicine, Republic of Uzbekistan Tashkent State Medical University
Author
-
- Keywords:
- COPD, arterial hypertension, chronic kidney disease, eGFR, E-selectin, type IV collagen, aldosterone, telmisartan, eplerenone, comorbidity
- Abstract
-
Background: Chronic obstructive pulmonary disease (COPD) is a leading global cause of disability and mortality, increasingly recognized as a systemic condition with multiorgan involvement. When complicated by arterial hypertension (AH), COPD patients face substantially elevated risk of renal dysfunction, yet this triad remains underinvestigated. Objective: To assess kidney dysfunction across COPD severity stages with and without comorbid AH, evaluate renal and vascular biomarkers, and investigate the efficacy of individualized therapy with Telsartan A (telmisartan + amlodipine) and eplerenone.Methods: 291 COPD+AH patients and 66 COPD-only controls were examined with pulmonary function tests, 24-hour blood pressure monitoring, and biomarker panels (cystatin-C, eGFR, aldosterone, E-selectin, type IV collagen, TNF-α, CRP).Results: COPD severity inversely correlated with eGFR and directly with all inflammatory and fibrotic markers; AH significantly worsened all renal parameters. Combined Telsartan A + eplerenone therapy improved FEV₁, eGFR, and reduced fibrotic/inflammatory markers. Conclusions: AH accelerates renal dysfunction in COPD. Early aldosterone, type IV collagen, and E-selectin measurement enables subclinical nephropathy detection. Telsartan A + eplerenone provides meaningful renoprotective benefit.
- References
-
1.Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. Update 2024. Available at: www.goldcopd.com
2.Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.
3.Doucet M, Rochette L, Hamel D. Incidence, Prevalence, and Mortality Trends in Chronic Obstructive Pulmonary Disease over 2001 to 2011: A Public Health Point of View of the Burden. Can Respir J. 2016;2016:7518287. doi:10.1155/2016/7518287
4.Wen G, Meng J, Wang H, et al. Prevalence of chronic obstructive pulmonary disease in high-risk populations at low, intermediate, high altitudes: a population based cross-sectional study in Yunnan Province, China. BMC Pulm Med. 2025;25(1):124. doi:10.1186/s12890-025-03565-5.Kahnert K, Jörres RA, Behr J, Welte T. The Diagnosis and Treatment of COPD and Its Comorbidities. Dtsch Arztebl Int. 2023;120(25):434-444. doi:10.3238/arztebl.m2023.027
6.Carter P, Lagan J, Fortune C, et al. Association of Cardiovascular Disease With Respiratory Disease. J Am Coll Cardiol. 2019;73(17):2166-2177. doi:10.1016/j.jacc.2018.11.063
- Downloads
- Published
- 2026-03-31
- Issue
- Vol. 2 No. 3 (2026)
- Section
- Articles
- License
-
This work is licensed under a Creative Commons Attribution 4.0 International License.
